SIETES :: 92751 citas

Resultados de la búsqueda por FINANCIACIÓN REFINAR BÚSQUEDA

1.

Sultana J, Moretti U, Addis A, Caduff P, Capuano A, Kant A, Laporte J-R, Lindquist M, Raine J, Sartori D, Trifirò G, Tuccori M, Venegoni M, van Puijenbroek E, Leone R. Workshop on the Italian pharmacovigilance system in the international context: critical issues and perspectives. Drug Saf 2019;42:mayo. [Ref.ID 103115]

2.

Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016. JAMA Intern Med 2018;178:julio. [Ref.ID 102882]

3.

Anónimo. Muscle drug determined too expensive for UK’s NHS. DIA Daily 2018:14 de agosto. [Ref.ID 102787]

4.

Mole B. “Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Ars Technica 2018:12 de abril. [Ref.ID 102511]

5.

Anónimo. Senate investigation reveals five manufacturers funded groups that acted as opioid “cheerleaders.”. DIA Daily 2018:12. [Ref.ID 102455]

6.

Hamel MB. Speed, safety, and industry funding — From PDUFA I to PDUFA VI. N Engl J Med 2017;377:2278-86. [Ref.ID 102166]

7.

Godlee F, Abbasi K, Bloom T. BMJ declares its revenues from industry. BMJ 2017;359:j4930. [Ref.ID 102109]

8.

Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study. BMJ 2017;359:j4619. [Ref.ID 102108]

9.

Anónimo. Insys Therapeutics faked cancer diagnoses to sell more of its opioid medication, senator says. DIA Daily 2017:11. [Ref.ID 102048]

10.

Anónimo. NICE considers eliminating Sanofi, Ipsen thyroid cancer drugs From Cancer Drug Fund. DIA Daily 2017:2. [Ref.ID 102033]

11.

Iacobucci G. NHS to stop funding homeopathy and some drugs in targeted savings drive. BMJ 2017;358:j3560. [Ref.ID 102013]

12.

Anónimo. WHO’s travel expenses exceed what it spends on some diseases. DIA Daily 2017:1. [Ref.ID 101587]

13.

Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]

14.

Anónimo. Former investors sue Valeant for failing to successfully market flibanserin. DIA Daily 2016:4. [Ref.ID 101011]

15.

Anónimo. UK appeals court rules NHS has authority to fund PrEP medication for HIV. DIA Daily 2016:1. [Ref.ID 100918]

16.

Anónimo. Infliximab biosimilar dubbed noninferior in independent clinical trial by Norwegian government. DIA Daily 2016:6. [Ref.ID 100841]

17.

Anónimo. NICE rejects Bristol-Myers’ Opdivo as general first-line NSCLC treatment. DIA Daily 2016:2. [Ref.ID 100810]

18.

Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 2016;316:858-71. [Ref.ID 100589]

19.

Anónimo. CMS paid $121 billion for drugs in 2014, data show. DIA Daily 2016:1. [Ref.ID 100587]

20.

Anónimo. Scientists develop alternative to morphine without some dangerous side effects. DIA Daily 2016:2. [Ref.ID 100586]